Par Pharmaceutical Begins Shipment of Ofloxacin Tablets for Bacterial Infections
SPRING VALLEY, N.Y. -- Pharmaceutical Resources, Inc. announced today that its principal subsidiary, Par Pharmaceutical, has received FDA approval for its ANDA for ofloxacin tablets in 200 mg, 300 mg and 400 mg strengths. Shipment of the 400 mg strength with branded sales of approximately $15 million will begin immediately. It is anticipated the remaining two strengths will ship sometime during the next quarter.
Ofloxacin is the generic version of Ortho-McNeil's Floxin, which is indicated for the treatment of adults with mild to moderate bacterial infections. The Floxin brand has annual sales of approximately $30 million.
Pharmaceutical Resources, Inc., a holding company, develops, manufactures, and distributes generic pharmaceuticals through its wholly owned subsidiary, Par Pharmaceutical.
Source: Par Pharmaceutical
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
